Short Interest in INVO Fertility, Inc (NASDAQ:IVF) Drops By 76.3%
by Doug Wharley · The Cerbat GemINVO Fertility, Inc (NASDAQ:IVF – Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totaling 79,020 shares, a decrease of 76.3% from the March 15th total of 333,878 shares. Currently, 4.9% of the company’s shares are short sold. Based on an average daily volume of 78,496 shares, the short-interest ratio is currently 1.0 days.
Wall Street Analysts Forecast Growth
IVF has been the topic of a number of research analyst reports. Maxim Group set a $20.00 price target on shares of INVO Fertility in a report on Tuesday, February 10th. Wall Street Zen upgraded shares of INVO Fertility from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, INVO Fertility presently has an average rating of “Moderate Buy” and an average target price of $20.00.
Check Out Our Latest Stock Report on INVO Fertility
INVO Fertility Price Performance
IVF remained flat at $2.01 during trading on Friday. 34,393 shares of the company’s stock were exchanged, compared to its average volume of 72,883. INVO Fertility has a 12 month low of $1.92 and a 12 month high of $384.00. The stock has a market capitalization of $3.25 million, a PE ratio of 0.00 and a beta of 2.64. The stock has a 50-day moving average of $4.10 and a two-hundred day moving average of $11.73.
Hedge Funds Weigh In On INVO Fertility
An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC purchased a new position in shares of INVO Fertility, Inc (NASDAQ:IVF – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility at the end of the most recent quarter. 12.02% of the stock is owned by hedge funds and other institutional investors.
INVO Fertility Company Profile
INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.
The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.